The mean corpuscular volume (MCV) is a hematological biomarker associated with COVID-19 mortality risk.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-07-01 Epub Date: 2025-06-26 DOI:10.1080/17520363.2025.2523235

Víctor Bernal-Dolores, José Manuel Reyes-Ruiz, Kim Rodríguez-Relingh, Gustavo Martínez-Mier

{"title":"The mean corpuscular volume (MCV) is a hematological biomarker associated with COVID-19 mortality risk.","authors":"Víctor Bernal-Dolores, José Manuel Reyes-Ruiz, Kim Rodríguez-Relingh, Gustavo Martínez-Mier","doi":"10.1080/17520363.2025.2523235","DOIUrl":null,"url":null,"abstract":"Aim: This study aimed to investigate the role of mean corpuscular volume (MCV) as a predictor of mortality due to COVID-19.Materials and methods: This retrospective, single-center, and longitudinal study included 122 patients with COVID-19.Results: Compared to the survivor's group, the non-survivors had higher MCV (92.13 ± 3.67 fL), neutrophil-to-lymphocyte ratio [NLR] (16.99 [21.31]), platelet-to-lymphocyte ratio [PLR] (350.33 [304.68]), and systemic immune-inflammation index [SII] (3684.92 [4073.25]) levels (p < 0.05 for all). The optimal cutoff values for predicting in-hospital COVID-19 mortality, determined by the Youden index, indicated that patients with MCV > 89 fL, NLR > 8.69, PLR > 418.08, or SII > 2149.36 were at a higher risk of death due to SARS-CoV-2 infection. The area under the curves (AUC) of NLR, SII, MCV, and PLR was sufficient for accurate prediction. COVID-19 patients with MCV > 89 fL and PLR > 418.08 were 3.65 (95% CI 1.03-12.87; p = 0.043) and 5.08 (95% CI 1.06-24.22; p = 0.041) times more likely to die than those without these values, respectively. MCV was positively correlated with age, mean corpuscular hemoglobin (MCH), urea, blood urea nitrogen (BUN), and creatinine.Conclusion: MCV > 89 fL and PLR > 418.08 at the time of hospital admission were associated with an increased COVID-19 mortality risk.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"577-587"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2523235","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: This study aimed to investigate the role of mean corpuscular volume (MCV) as a predictor of mortality due to COVID-19.

Materials and methods: This retrospective, single-center, and longitudinal study included 122 patients with COVID-19.

Results: Compared to the survivor's group, the non-survivors had higher MCV (92.13 ± 3.67 fL), neutrophil-to-lymphocyte ratio [NLR] (16.99 [21.31]), platelet-to-lymphocyte ratio [PLR] (350.33 [304.68]), and systemic immune-inflammation index [SII] (3684.92 [4073.25]) levels (p < 0.05 for all). The optimal cutoff values for predicting in-hospital COVID-19 mortality, determined by the Youden index, indicated that patients with MCV > 89 fL, NLR > 8.69, PLR > 418.08, or SII > 2149.36 were at a higher risk of death due to SARS-CoV-2 infection. The area under the curves (AUC) of NLR, SII, MCV, and PLR was sufficient for accurate prediction. COVID-19 patients with MCV > 89 fL and PLR > 418.08 were 3.65 (95% CI 1.03-12.87; p = 0.043) and 5.08 (95% CI 1.06-24.22; p = 0.041) times more likely to die than those without these values, respectively. MCV was positively correlated with age, mean corpuscular hemoglobin (MCH), urea, blood urea nitrogen (BUN), and creatinine.

Conclusion: MCV > 89 fL and PLR > 418.08 at the time of hospital admission were associated with an increased COVID-19 mortality risk.

查看原文本刊更多论文

平均红细胞体积（MCV）是与COVID-19死亡风险相关的血液学生物标志物。

目的：本研究旨在探讨平均红细胞体积（MCV）作为COVID-19死亡率预测因子的作用。材料和方法：这项回顾性、单中心、纵向研究纳入了122例COVID-19患者。结果：与存活组相比，非存活组MCV（92.13±3.67 fL）、中性粒细胞与淋巴细胞比值（NLR）（16.99[21.31]）、血小板与淋巴细胞比值（PLR）（350.33[304.68]）、全身免疫炎症指数（SII）（3684.92[4073.25]）水平（p 89 fL、NLR > 8.69、PLR > 418.08、SII > 2149.36）均高于存活组。NLR、SII、MCV和PLR的曲线下面积（AUC）足以准确预测。COVID-19患者MCV > 89 fL和PLR > 418.08为3.65 (95% CI 1.03-12.87；p = 0.043)和5.08 (95% CI 1.06-24.22；P = 0.041)的死亡率是没有这些值的人的两倍。MCV与年龄、平均红细胞血红蛋白（MCH）、尿素、血尿素氮（BUN）、肌酐呈正相关。结论：入院时MCV bbb89 fL和PLR bbb418.08与COVID-19死亡风险增加相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.